TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (VRTX) (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

For more information: Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 ...

Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Investors: [email protected] ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

OSAKA, Japan & BOSTON, June 23, 2025--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Vertex Pharmaceuticals ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

OSAKA, Japan & BOSTON, June 23, 2025--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, ...